Compare FEMY & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | NMTC |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2M | 39.5M |
| IPO Year | 2021 | 2010 |
| Metric | FEMY | NMTC |
|---|---|---|
| Price | $0.50 | $0.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $5.50 | $1.98 |
| AVG Volume (30 Days) | ★ 442.0K | 172.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.60 | ★ 80.43 |
| EPS | N/A | ★ N/A |
| Revenue | $1,629,108.00 | ★ $9,097,692.00 |
| Revenue This Year | $59.47 | N/A |
| Revenue Next Year | $150.54 | $31.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 51.97 | ★ 163.47 |
| 52 Week Low | $0.31 | $0.40 |
| 52 Week High | $1.63 | $1.15 |
| Indicator | FEMY | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 48.42 |
| Support Level | $0.48 | $0.69 |
| Resistance Level | $0.58 | $0.75 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 12.87 | 24.88 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.